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Treg cells are critical for the prevention of autoimmune diseases and are thus prime can-
didates for cell-based clinical therapy. However, human Treg cells are “plastic”, and are
able to produce IL-17 under inflammatory conditions. Here, we identify and character-
ize the human Treg subpopulation that can be induced to produce IL-17 and identify its
mechanisms. We confirm that a subpopulation of human Treg cells produces IL-17 in
vitro when activated in the presence of IL-1β, but not IL-6. “IL-17 potential” is restricted
to population III (CD4+CD25hiCD127loCD45RA−) Treg cells expressing the natural killer
cell marker CD161. We show that these cells are functionally as suppressive and have
similar phenotypic/molecular characteristics to other subpopulations of Treg cells and
retain their suppressive function following IL-17 induction. Importantly, we find that
IL-17 production is STAT3 dependent, with Treg cells from patients with STAT3 muta-
tions unable to make IL-17. Finally, we show that CD161+ population III Treg cells accu-
mulate in inflamed joints of patients with inflammatory arthritis and are the predominant
IL-17-producing Treg-cell population at these sites. As IL-17 production from this Treg-
cell subpopulation is not accompanied by a loss of regulatory function, in the context of
cell therapy, exclusion of these cells from the cell product may not be necessary.
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Introduction
Physiological maintenance of peripheral tolerance is critically
dependent on a population of circulating cells committed to
suppressor function. Of these, CD4+ “regulatory” T (Treg) cells
expressing high levels of the IL-2 receptor α chain (CD25) and the
transcription factor FOXP3 are the most important [1]. Treg cells
suppress the proliferation and effector function of CD4+CD25−
effector T (Teff) cells to polyclonal and antigen-specific stim-
uli [2]. Loss of the Treg-cell lineage, through mutations in the
FOXP3 gene, manifests in life-threatening X-linked autoimmune
diseases in mammals (the Scurfy strain in mice [3] and human
immunodysregulation, polyendocrinopathy, enteropathy, and
X-linked (IPEX) syndrome [4]). In addition, functional deficits
in Treg cells have been proposed to contribute to the development
or severity of autoimmune diseases in man [5, 6]. Conversely,
administration of Treg cells in murine models controls experi-
mental allergic [7] and autoimmune diseases [8] and can prevent
rejection of allografts [9] while in borderline or acutely rejecting
human renal and liver transplant specimens, Treg-cell numbers
correlate positively with better outcomes [10, 11]. These proper-
ties, together with the observation that human Treg cells can be
expanded ex vivo, either polyclonally [12,13] or for a given speci-
ficity [14], make Treg cells ideal candidates for tolerance-inducing
cell therapy in human autoimmune diseases and transplantation
[15]. Indeed, small-scale trials have demonstrated beneficial out-
comes in the prevention or treatment of postbone marrow trans-
plantation human graft versus host disease [16].
Emerging concepts of mammalian CD4+ T-helper (Th) lineage
commitment [17] suggest that Th-cell fate is not as irreversible
as previously thought, and that lineage reprogramming can occur
through the inducible expression of key transcription factors [17].
Differentiation of Treg cells from na¨ıve murine precursors is recip-
rocally linked to that of the Th17-cell lineage through a common
requirement for TGF-β with the presence or absence of IL-6 skew-
ing differentiation toward Th17 or Treg cells, respectively [18].
Th17 cells express the transcription factors ROR-α and ROR-γt
(RORA and RORC2 in humans) and produce the proinflammatory
cytokine IL-17. The Th17-cell lineage is functionally nonredun-
dant for the elimination of extracellular pathogens [19] and is a
major pathogenic lineage in the development and/or activity of
autoimmune diseases and organ rejection in humans [20]. How-
ever, Th17 cells generatedwith TGF-β and IL-6 demonstrate unsta-
ble lineage commitment and undergo fate switching to alternate
lineages, in particular Th1, both in vitro and in vivo [21–23].
Likewise, Treg-cell lineage commitment has recently been
questioned, with demonstrations that their regulatory function
can be subverted in the context of infection [24] and that they can
be induced to express the phenotypic profile of Th17 cells in the
presence of inflammatory cytokines, namely IL-1 and IL-6 [25–27].
However, lineage reprogramming of Treg cells remains contro-
versial, as fate-mapping studies in murine models have failed to
replicate the plasticity data [28]. Nevertheless, “Th17 converted”
Treg cells have been identified in inflamed, but not in noninflamed,
bowel from patients with Crohn’s disease inman [29]. It is unlikely
that these data are the result of “outgrowth” of Foxp3− non-Treg
contaminants as these cells do not expand when co-transferred
with Foxp3+ populations in the lymphopenic hosts [30]. Indeed, it
was recently shown that specific human Treg-cell subpopulations
can evolve that functionally mirror analogous effector Th-cell sub-
sets, guided by proinflammatory cues during an immune response
[31]. Thus, Treg-cell plasticity is of fundamental importance to
understand the development of autoimmune diseases and antici-
pation of adverse effects in programs of Treg-cell-based therapy.
In this study, we confirm that human Treg cells in vitro pro-
duce IL-17 when activated in the presence of IL-1β, in a STAT3-
dependent manner and that this function is the prerogative of a
subpopulation of Treg cells within population III [32] expressing
CD161. However, these cells maintain their suppressive function.
Finally, we show that these Treg cells are enriched within the
inflamed joints of patients with inflammatory arthritis relative to
matched peripheral blood (PB).
Results
Human Treg cells produce IL-17 in vitro
It has been shown both in murine models and in man that
Treg cells are plastic. In order to identify the population of Treg
cells responsible for the conversion to IL-17-producing cells and
the mechanisms behind this event, freshly isolated bead-enriched
“whole” human Treg cells (CD4+CD25+) were initially activated
in vitro in the presence of IL-1β, as previously reported [25, 26],
and/or IL-2. We observed that Treg cells produced IL-17 when in
the presence of IL-1β and the highest levels were found when IL-2
was further added to the culture (Fig. 1A), in part due to IL-2-
mediated increased expression of IL-1R1 (Supporting Information
Fig. 1), as previously shown [12]. The increased IL-17 mediated
by IL-1β was confirmed with intracellular staining (ICS) and was
accompanied by a reduction in FOXP3 (Fig. 1B and C). A negative
correlation between the percentage of IL-17 and FOXP3 single-
positive cells was observed following activation of Treg cells in
the presence of IL-1β plus IL-2 (r2 = 0.79, p < 0.05) (Fig. 1C).
The presence of IL-2, however, maintained a higher percentage of
FOXP3+ cells in ex vivo activated Treg cells but the addition of
IL-1β antagonized this effect (Fig. 1C). The conversion of
Treg cells to Th17 cells, rather than outgrowth of a contaminat-
ing population, was suggested by repeated observation of cells
that were double positive for both FOXP3 and IL-17 (Fig. 1D,
top panel), plus a kinetic transition through a double-positive
phase (Fig. 1D, lower panel and Supporting Information Fig. 2),
indicative of a transitional stage. In the double-positive popula-
tion, FOXP3 levels were lower in those cells expressing higher
IL-17 levels (Fig. 1D).
Appropriate patterns of the transcription factors FOXP3 and
RORC were identified in Treg cells treated with exogenous
cytokine immediately after culture: IL-1β reduced FOXP3 mRNA
and elevated RORC transcripts, whereas IL-2 maintained high
FOXP3 but inhibited RORC transcription, as has been documented
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Figure 1. Human Treg cells are induced to produce IL-17 and to downregulate FOXP3 by IL-1β. (A) “Total” CD4+CD25+ Treg cells from healthy
donors were activated with anti-CD3/CD28 in medium supplemented with IL-1β, IL-2 or IL-1β+IL-2. IL-17 production was measured by ELISA
and shown as mean of 12 donors. (B) A representative example of ICS for IL-17 and FOXP3 in which Treg cells were activated for 5 days
with anti-CD3/CD28 together with the cytokines indicated. Data shown are from one experiment representative of five performed. (C) Cumu-
lative data from five independent experiments showing FOXP3 staining in Treg cells activated with anti-CD3/CD28 together with cytokines
(left) and negative correlation between the percentages of FOXP3+ and IL-17+ cells (right; r2 = 0.79, p < 0.05). The solid and dashed lines
show the linear regression and 95% confidence interval, respectively (right). (D) A representative ICS for FOXP3 and IL-17 expression in
Treg cells activated with anti-CD3/CD28 in the presence of IL-1β and IL-2, highlighting the double-positive population on day 4 (top, upper right
quadrant) plus a kinetic transition through a double-positive phase (bottom). Data shownare fromone experiment representative of five performed.
(E) qRT-PCR for FOXP3 (left) and RORC (right) from Treg cells activated with anti-CD3/CD28 with and without cytokine. Data are normalized to
unsupplemented medium; shown are mean +SD of triplicate samples and are from one experiment representative of two performed. (F) Repre-
sentative Western blot showing total and phosphotylated (pY) STAT3 in Treg cells activated with anti-CD3/CD28 in the presence of the cytokines
indicated. Data shown are from one experiment representative of four performed. (G) IL-17 production from Treg cells of a healthy control and
two patients with hyper-IgE syndrome activated with anti-CD3/CD28 and exogenous cytokine. Data are shown as mean +SD and are from one
experiment. *p < 0.05, One-way ANOVA (A), paired t-test (C, left panel), F test (C, right panel).
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in mouse T cells [33]. The combination of the two cytokines
showed dominant effects of IL-1β, characterized by quantitatively
high RORC and low-FOXP3 transcripts (Fig. 1E). However, the
relatively small changes in transcription factor profiles observed
(Fig. 1E) and the relatively low-frequency conversion seen with
ICS (Fig. 1B) suggested that Th17 plasticity is a feature of some,
but not all, cells contained in the “whole” human Treg-cell popu-
lation (see below).
As na¨ıve T-cell lineage commitment to Th17 is critically depen-
dent on STAT3 activation [34], we assessed the status of STAT3-
tyrosine phosphorylation of Treg cells activated in the pres-
ence of IL-1β, IL-2, or the combination of the two cytokines
(Fig. 1F). As the earliest time point at which increased IL-17
could clearly be detected following IL-1β treatment of Treg-cell
cultures was 3 days, cell extracts were prepared at this time
point. STAT3 phosphorylation was significantly induced and sus-
tained when Treg cells were activated in the presence of IL-1β or
IL-1β+ IL-2 (Fig. 1F). In contrast, STAT5 tyrosine phosphorylation
remained at similar levels in all conditions, as with TCR activa-
tion alone. Similar results were obtained from cells stimulated for
5 days (data not shown). These observations were corroborated
by ICS for pY-STAT3 and pY-STAT5 in Treg cells (Supporting
Information Fig. 3). Of note, and different from the mouse, IL-6
did not induce production of IL-17 by Treg cells (data not shown).
Thus, additional molecular changes induced by IL-1β, but not
IL-6, are required along with STAT3 activation for the expression
of IL-17 by Treg cells.
Altogether, these findings indicate that increased RORC expres-
sion and pSTAT3 levels may compete with pSTAT5 to positively
regulate the IL-17 locus and contribute to the increased IL-17
expression in IL-1β-treated Treg cells. To confirm the impor-
tance of STAT3 signaling in IL-1β-induced IL-17 production by
Treg cells, Treg cells were separated from the PB of two
patients with hyper-IgE syndrome (OMIM 147060). These sub-
jects had dominant negative mutations in the SH2 domain
of STAT3, impairing STAT3 activation [35]. Treg cells from
these two patients and one healthy control were activated
in culture medium containing IL-1β and IL-2, and super-
natants tested 5 days later for IL-17 by ELISA. Although
healthy donor Treg cells produced IL-17 in the presence of
IL-1β and IL-2, Treg cells from STAT3 mutant patients pro-
duced negligible amounts (patient 1: 0 pg/mL; patient 2:
6 pg/mL) (Fig. 1G). Thus, the importance of STAT3 signaling for
IL-17 production by Treg cells is firmly established as Treg cells
from hyper-IgE syndrome patients with defective STAT3 proteins
cannot differentiate along this pathway.
A distinct subpopulation of human Treg cells
undergoes IL-17 induction in vitro
Given the relatively small changes in transcription factor profiles
observed (Fig. 1E) and the relatively low frequency of conversion
seen with ICS (Fig. 1B) in “whole” bead-enriched CD4+CD25+
Treg cells, we hypothesized that IL-17 potential is restricted to
one or more subpopulations of human Treg cells. Treg cells were
FACS sorted into three subpopulations based on the expression
of FOXP3 and CD45RA, namely CD4+CD25++CD127loCD45RA+
(population I), CD4+CD25+++CD127loCD45RA− (population II),
and CD4+CD25++CD127loCD45RA− (population III), as recently
published [32] (Fig. 2A and Supporting Information Fig. 4). Fol-
lowing stimulation in vitro in the presence of IL-1β and IL-1β+IL-2,
only population III was found to produce IL-17 (Fig. 2B).
To further refine the converting subpopulation of Treg cells,
we tried to identify additional markers that can characterize it. As
the NK-cell marker CD161 was shown by others to identify Th17
precursors among CD4+ human cells [36], its expression on popu-
lations I, II, and III was evaluated and was clearly more prevalent
on Treg cells in population III than in populations I and II (Fig. 2C
and D). Treg cells expressing CD161 (population III CD161+) and
their CD161− counterparts (population III CD161−) were FACS
sorted, together with CD161− cells from population I (population
I CD161−) and in vitro Th17 conversion assessed as before. There
were insufficient cells for cell sorting of CD161+ Treg cells from
populations I and II to be included here. As shown in Figure 2E,
only population III CD161+ cells produced IL-17 under IL-17-
inducing conditions and did not convert in the absence of inflam-
matory signals. This latter point is important as it demonstrates
that the now IL-17-producing population III CD161+ cells are not
derived from previously committed, contaminating, Th17 cells.
To determine the frequency of IL-17-producing Treg cells, we
performed ICS for RORC and IL-17 in the cell sorted populations
after culture with anti-CD3/CD28/IL-1β/IL-2. A significant pro-
portion of population III CD161+ cells produced IL-17, with the
majority of cells also expressing RORC (Fig. 2F). This was not
the case for population I or III CD161− Treg cells (Fig. 2F). The
induction of RORC and Interferon-regulatory factor 4 (IRF-4), a
critical transcription factor in Th17 differentiation [37], in these
populations was confirmed by qRT-PCR, showing clearly a large
upregulation of RORC in population III CD161+ activated under
IL-17-inducing conditions (Fig. 2G, upper panels) and a similar
induction of IRF-4 (Fig. 2G, lower panels), suggesting that we
have correctly identified a subset of Treg cells with IL-17 poten-
tial. In these cells, we observed a similar activation of STAT3 with
IL-1β as before (data not shown).
Others have described CCR6 as a marker of Treg cells capable
of producing IL-17 [25, 31, 36]. However, when we stained for
CCR6 and IL-1R1 on population III Treg cells, we did not identify a
significant difference between population III CD161+ and CD161−
cells in expression of CCR6 nor IL-1R1 (Supporting Information
Fig. 5). Therefore, we concluded that CD161 is the marker that
identifies Treg cells capable of being induced to produce IL-17 and
that this property is not related to higher baseline expression of
the IL-1R.
Population III CD161+ Treg cells express less FOXP3
but are as suppressive as other Treg cells
To further characterize the population of interest, FOXP3 expres-
sion was evaluated. Population III CD161+ Treg cells expressed
less FOXP3 protein in comparison with population III CD161−
C© 2013 The Authors. European Journal of Immunology published by
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Figure 2. Population III CD161+ Treg cells are the population with “IL-17 potential”. (A) The gating strategy, adapted fromMiyara et al. [32], used to
identify populations I, II, and III CD4+CD25hiCD127lo Treg cells is shown. A representative example frommultiple experiments is shown (please see
Supporting Information Fig. 4 for full gating pathway). (B) The IL-17 concentrations in supernatants of populations I, III, and II Treg cells activated
with anti-CD3/CD28 coated beads in the presence of medium only (medium) or medium supplemented with IL-1β and IL-2 (IL-1β+IL-2) for 5 days
were determined by ELISA. Data are shown as mean + SD pooled from three experiments using blood from three independent healthy donors.
(C, D) CD161 expression on populations I, III, and II Treg cells was determined by flow cytometry, (C) a representative example and (D) the mean
+ SD of five donors is shown. (E) IL-17 production by population I CD161−, population III CD161−, and population III CD161+ Treg cells activated
with anti-CD3/CD28 coated beads in the presence of medium alone (medium) or medium supplemented with IL-1β and IL-2 (IL-1β+IL-2) for 5 days
are shown as mean +SD of data pooled from five experiments performed * p < 0.05, paired t-test. (F) RORγt and IL-17 expression in population I
CD161−, population III CD161−, and population III CD161+ Treg cells after 5 days activation with anti-CD3/CD28 coated beads and IL-1β+IL-2 were
determined by flow cytometry. Values in the gates are percentages. Data shown are representative of two independent experiments performed.
(G) qRT-PCR showing fold induction of RORC (top) and IRF-4 (bottom) in population I CD161−, population III CD161−, and population III CD161+
Treg cells activated with anti-CD3/CD28 coated beads in the presence of medium alone (medium) or medium supplemented with IL-1β and IL-2
(IL-1β+IL-2) for 5 days. The panels show individual data from three independent healthy donors.
cells (Fig. 3A and B). Given the lower expression of FOXP3,
and previous suggestions that population III is nonsuppressive
[32], we tested their capacity to suppress proliferation of auto-
logous CFSE-labeled Teff cells. We found that suppressive func-
tion in population III CD161+ Treg cells was similar to other
Treg-cell populations (Fig. 3C and D). Likewise, their ability
to suppress production of IFN-γ and IL-2 production from Teff
cells was comparable to those of other Treg subpopulations
(Fig. 3E and F). These data demonstrate that population III
CD161+ cells have regulatory properties and further confirmed
that these are not contaminating Teff cells of the Th17 or Th1
lineage.
C© 2013 The Authors. European Journal of Immunology published by
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Figure 3. Population III CD161+ Treg cells express less FOXP3 but are as suppressive as other Treg-cell subpopulations. (A) A representative
histogram of FOXP3 expression in freshly isolated Treg-cell populations III CD161− (solid line) and III CD161+ (dashed line) relative to isotype
control (shaded) is shown. (B) The percentage of FOXP3+ cells is also shown as mean + SD of four independent donors * < 0.05, paired t-test.
(C, D) The suppressive effects of freshly isolated population I CD161−, population III CD161−, and population III CD161+ cells on proliferation of
autologous CFSE-labeled Teff cells are shown as (C) a representative flow cytometry example and (D) mean + SD of five samples pooled from five
independent experiments. (E, F) The suppressive effects of population I CD161−, population III CD161− and population III CD161+, Treg cells on
(E) IFN-γ and (F) IL-2 production by autologous Teff cells were determined by supernatant cytokine concentrations (left) and percentage suppression
(right) and expressed as mean + SD of two samples pooled from two independent experiments. (G) The suppressive function of population III
CD161+ Treg cells after culture under IL-17-inducing conditions was determined by inhibition of CFSE dilution and is shown as a representative
example (left) and mean +SD of two donors (right). (H) The concentration of IFN-γ (top left) and IL-2 (bottom left) and the percentage suppression
of each cytokine (right) are shown as mean + SD of two samples pooled from two independent experiments. *p < 0.05, one-way ANOVA.
To determine whether these cells lose their suppressive func-
tion upon IL-17 induction, population III CD161+ Treg cells were
cultured under IL-17-inducing conditions for 5 days, then washed
and co-cultured with autologous CFSE-labeled Teff cells in stan-
dard suppression assays. Not only did the Treg cells retain sup-
pressive function (Fig. 3F and G), but their suppressive capacity
was also enhanced following exposure to IL-17-inducing condi-
tions (mean ± SD percentage suppression 56.8 ± 14.5% ver-
sus 92.0 ± 1.3% pre- and post-IL-17 induction, respectively;
p < 0.05). Similarly, these Treg cells potently regulated IFN-γ
and IL-2 production from Teff cells (Fig. 3H) after they had been
exposed to IL-17-inducing conditions. These data suggest that
IL-17 production is compatible with potent suppressive function
in vitro.
Population III CD161+ Treg cells are phenotypically
similar to other Treg-cell subpopulations
Population III CD161+ Treg cells were further characterized to
determine how similar they are to other Treg-cell subpopulations
at baseline.We first examined expression of CD39, an ecto-enzyme
involved in Treg-cell function [38], and HLA-DR, a marker of
Treg cells with early contact-dependent suppression [39], by flow
cytometry, comparing CD161− with CD161+ Treg cells in popula-
tion III and found no significant differences between the percent-
ages of Treg cells that express thesemarkers on the two subpopula-
tions, although there was a tendency to lower expression of CD39
(Fig. 4A). Likewise, we compared expression of FOXP3, RORC,
CTLA-4 (essential for Treg-cell function [40]), ICOS (Inducible
C© 2013 The Authors. European Journal of Immunology published by
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Figure 4. Immunophenotyping of
freshly isolated population III CD161+
Treg cells. (A) The percentages of
Treg cells staining positive for CD39
(left) and HLA-DR (right) in popu-
lation III CD161− and CD161+ Treg
cells is shown. Paired data from five
independent experiments are shown.
(B–G) Gene expression profiling of
freshly isolated population I CD161−,
population III CD161−, andpopulation
III CD161+ Treg cells for (B) FOXP3,
(C) RORC, (D) FOXP3/RORC ratio,
(E) CTLA-4, (F) ICOS, and (G) Helios
is shown. Individual data from
three independent healthy donors are
shown.
T-cell co-stimulator; ICOS+ Treg cells suppress DCs via IL-10
and TGF-β [41]), and Helios (a putative marker of thymically
derived Treg cells [42]) by qRT-PCR on populations I CD161−,
III CD161−, and III CD161+ Treg cells obtained from freshly sorted
healthy donor Treg cells (Fig. 4B–G). As noted above, population
III CD161+ Treg cells express less FOXP3 than the other popula-
tions (Fig. 4B) and variable basal levels of RORC with a tendency
for higher expression in CD161+ cells (Fig. 4C), resulting in a
quantitative FOXP3/RORC mRNA ratio in population III CD161+
Treg cells that favors RORC, compared with that of the other two
populations (Fig. 4D).
At baseline, population III CD161+ Treg cells expressed sim-
ilar amounts of CTLA-4 (Fig. 4E) but lower quantities of Helios
(Fig. 4G) than population III CD161− Treg cells, suggesting a
difference in these two populations either in their origin or con-
text of generation. Consistent with this notion, analysis of “na¨ıve”
Treg cells from fresh human umbilical cord blood-derived CD4+
T cells, identified few population III CD161+ Treg cells, which
produced only minimal amounts of IL-17 (Supporting Informa-
tion Fig. 6). ICOS expression was more variable, being lower
in two out of three donors in population III CD161+ Treg cells
(Fig. 4F).
Overall, these data indicate that CD161-expressing Treg cells
are not only functionally suppressive, but also possess phenotypic
molecular characteristics that enable them to further differentiate
to Th17 cells upon IL-1β stimulation.
Population III CD161+ Treg cells are increased
within inflamed joints
Having identified the human Treg-cell subpopulation with IL-17
potential, and established that this cell type is phenotypically sim-
ilar to other human Treg cells within population III, we next
sought to determine whether these cells are present within actively
inflamed human environments. We therefore enumerated popu-
lation III CD161+ Treg cells from paired PB and synovial fluid
(SF) (of inflamed knee) samples of five patients with inflamma-
tory arthritis (n = 1 rheumatoid arthritis, n = 4 psoriatic arthritis;
Table 1) by flow cytometry (Fig. 5).
The percentage of CD161+ cells within population III
Treg cells was significantly higher in SF than PB (Fig. 5A), suggest-
ing that there is an accumulation of Treg cells with IL-17 potential
at inflamed sites relative to PB. When we studied expression of
HLA-DR and CD39 on Treg cells from these sites, we identified
a greater percentage of HLA-DR expressing cells in population III
Treg cells, whether CD161− or CD161+, in the joint fluid com-
pared to PB (Fig. 5B), indicating that these cells were recently
activated, as previously suggested [43]. Similar to the pattern
C© 2013 The Authors. European Journal of Immunology published by
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Table 1. Clinical characteristics of patients with inflammatory arthritis
Age Sex Pathology Disease RhF Erosive Medication DAS28 ESR CRP
duration (years)
74 M RA 5 + Y MTX 4.23 18 18
51 M PsA 25 – N NSAID 4.3 20 17
72 M PsA 13 + Y Etanercept 3.5 N/A 140
34 M PsA 11 – N Etanercept 3.98 83 141
37 F PsA 6 – N MTX 4.54 80 32
CRP: C-reactive protein; DAS28: disease activity score using 28 joint counts; ESR: erythrocyte sedimentation rate; MTX: methotrexate; N/A: not
available; NSAID: nonsteroidal anti-inflammatory drugs; PsA: psoriatic arthritis; RA: rheumatoid arthritis; RhF: rheumatoid factor.
Figure 5. Characteristics of population III Treg cells in PB and SF from patients with inflammatory arthritis. (A) The percentage of CD161+ cells
in population III Treg cells is shown. (B, C) The percentages of HLA-DR+ and CD39+ cells in population III CD161− (open symbols) and population
III CD161+ (filled symbols) Treg cells in PB and SF. Samples and cells from the same patients are connected with a dotted or solid line. (D) IL-17
production by paired population III CD161− (left) and CD161+ (right) Treg cells in SF (solid line histograms) and PB (dashed line histograms) of two
donors with inflammatory arthritis is shown. Numbers in each histogram show percentage positive for IL-17 in SF (top) and PB (bottom). *p < 0.05,
paired t-test.
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observed in healthy donors (Fig. 4A), a slightly lower percentage
of CD39-expressing cells were found in PB population III CD161+
Treg cells compared with their CD161− counterparts (Fig. 5C).
In the SF, the percentage of CD39+ cells was increased in all
population III CD161− Treg cells and in all CD161+ Treg cells
compared to their blood counterparts (Fig. 5B). To determine
which Treg-cell subpopulation produces IL-17 in the inflamma-
tory environment, we stained paired PB and SF mononuclear cells
for IL-17 and gated on subpopulations of Treg cells. In both PB
and SF, although the majority of IL-17 was produced by non-Treg
cells (Treg cells accounted for 15 ± 1.41% of IL-17+ cells), IL-17
production from Treg cells was restricted to CD161+ population
III (Fig. 5D), with SF Treg cells producing more IL-17 than their
paired PB counterparts. Taken together, these data suggest that
CD161+ Treg cells with the potential for IL-17 induction accumu-
late at sites of inflammation and are the principal source of IL-17
from Treg cells.
Discussion
Here, we set out to identify the human Treg subpopulation
that can be induced to produce IL-17 and to characterize its
phenotypic features. We confirm that a proportion of the human
Treg-cell pool in circulation (approximately 5–10% of total
Treg cells) can be induced in vitro to produce IL-17 when activated
in the presence of IL-1β, in a STAT3-dependent manner. We fur-
ther demonstrate that “IL-17 potential” is isolated to population III
(CD4+CD25++CD127loCD45RA−) Treg cells and that this effect is
almost exclusively restricted to a subpopulation within population
III that expresses the NK-cell marker CD161. Opposed to a previous
key publication [32], we find that at baseline these cells are func-
tionally as suppressive and have similar phenotypic/molecular
characteristics to subpopulations I and II of Treg cells, but that
they have the potential to produce IL-17 while maintaining their
suppressive function. Finally, we show that Treg cells with popu-
lation III phenotypic features accumulate at sites of inflammation
and that these cells are the main source of IL-17 from Treg cells
at those sites.
CD4+CD25+ Treg cells in inflammatory arthritis have been
studied extensively over the past years. Although conflicting data
exist regarding Treg-cell frequencies and function in PB of inflam-
matory arthritis patients, studies generally agree on an increase
in Treg-cell frequencies in the SF, that are functionally sup-
pressive ex vivo, sometimes at an enhanced level [44–47]. The
inflammatory environment of the arthritic joint may, however,
interfere with Treg-cell-mediated suppression either by inducing
resistance to suppression in Teff cells or by subverting Treg-cell
function [48]. Our demonstration that a distinct population of
CD4+CD25++CD127loCD45RA− Treg cells expressing CD161 is
increased at the site of inflammation in inflammatory arthritis
and that IL-17 production from Treg cells is restricted to these,
suggests that these cells may be prone to producing IL-17 in
the presence of IL-1β, which is present at increased levels in
the inflamed arthritic joint. It remains to be determined, how-
ever, whether such an induction occurs in vivo. Our in vitro
data indicate that CD161+ population III Treg cells in a nonin-
flammatory environment are fully suppressive and phenotypically
express similar markers to other Treg cells, in particular CD39,
HLA-DR, and CTLA-4. In addition, after culture in IL-17-inducing
conditions in vitro, these cells not only retain their suppressive
function but demonstrate enhanced regulatory properties, consis-
tent with those seen in Treg cells from inflamed SF. Using an in
vitro model, we recently showed that activated monocytes, which
are abundantly present at sites of inflammation and are potent
producers of IL-1β, increase the percentage of IL-17+ cells in
human CD4+CD25+CD127loCD45RO+ Treg cells; however, these
Treg cells maintained their ability to suppress effector T-cell pro-
liferation concurrently with IL-17 production [49]. This is in line
with recent findings that IL-17 production does not equivocally
define a pro-inflammatory and destructive phenotype but can also
contribute to tissue repair and integrity [50].
Of particular interest is FOXP3 expression in population III
CD161+ Treg cells. Of the three subpopulations, we studied (pop-
ulations I CD161−, III CD161−, and III CD161+), population III
CD161+ expressed the least FOXP3 mRNA and FOXP3 protein at
baseline. Coupled to this, RORC levels were higher in the CD161+
population resulting in a FOXP3/RORC ratio that was the lowest of
the three populations, making these cells appear poised for IL-17
production. As FOXP3 physically interacts with and inhibits RORC
and RORA, preventing them from binding their genomic targets
[51], reduced FOXP3 expression in plastic Treg-cell subpopula-
tions could, in addition, be permissive for activation of the RORC
transcriptional programme.
In contrast to our observations that population III Treg cells
are highly suppressive, Miyara et al. [32] described population III
Treg cells as nonregulatory. This discrepancy may be related to
differences in Teff-cell populations and stimulation conditions
selected in suppression assays. Likewise, murine fate-mapping
models that demonstrate limited in vivo Treg-cell plasticity [28],
although elegant, have sufficient limitations [30] that they do not
provide definitive answers to the question of Treg-cell plasticity
and do not explain why T cells with the characteristics we describe
in this manuscript have also been identified at inflamed, but not
healthy, areas in the bowel of patients with Crohn’s disease [29].
Mechanistically, both IL-1β and STAT3 signaling appears crit-
ical for induction of IL-17 in human Treg cells. Although the
requirement for STAT3 activation for Th17-cell differentiation in
conventional T cells is well established [34], it is likely that STAT3
activation in Treg cells occurs through nonconventional means, as
described previously in nonimmune cells [52], because the IL-1R
does not directly interact with JAK proteins. This may also explain
why classical STAT3 activators, such as IL-6, do not appear to play
a role in IL-17 induction in human Treg cells in this or other studies
[25, 26]. IL-2 has previously been shown to antagonize conven-
tional Th17 differentiation in murine cells [33], so the synergistic
effect of IL-2 with IL-1β to promote IL-17 induction in human
Treg cells appears unexpected. However, in human cells, the com-
mon γ chain (γc) using cytokines, including IL-2, have been shown
to potently activate Th17 signature cytokines in specific CD4+
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memory T cells [53] and, therefore, may stimulate CD161+ Treg
cells in a similar manner. We believe that one key role of IL-2 in
IL-17 induction from Treg cells is to upregulate IL-1R1, as has also
been demonstrated by others [12], sensitizing Treg cells to IL-1
signaling.
These observations suggest that Treg cells are not termi-
nally differentiated and can alter their phenotype as dictated by
their local cytokine microenvironment. That some, but not all
Treg cells, have the capacity to express programs of other lineages
is important, as universal potential to undergo fate switching to
pro-inflammatory lineages in Treg cells at the site of inflamma-
tion could represent a greater risk for the development of auto-
immune diseases than is seen during the normal human response
to infectious challenges. In the context of Treg-cell-based therapy
for induction of tolerance to transplanted organs or production of
remission in autoimmune diseases, transfer of a Treg-cell product
that contains a subpopulation that can express pro-inflammatory
cytokines could potentially be damaging. However, our data sug-
gests that IL-17 production from a Treg-cell subpopulation with
“IL-17 potential” is not necessarily accompanied by a loss of reg-
ulatory function, so exclusion of these cells from the cell product
for Treg-cell therapy, for example by CD161 depletion, may not
be necessary. This assertion is supported by Treg-cell-based clini-
cal trials in the context of bone marrow transplantation [16] and
type 1 diabetes mellitus [54], in which suggestive adverse effects
have not been reported.
Materials and methods
T-cell separation, FACS sorting, and flow cytometry
CD25+ and CD25− CD4+ T cells were separated from human buffy
coats as previously described [55]. Baseline FOXP3 and IL-17
expression is shown in Supporting Information Figure 2A. Flow
cytometry and FACS sorting (routinely to a purity ≥95%), using
CD4+ T cells stained for CD4-Qdot605, CD161-allophycocyanin,
CD127-PerCP-Cy5.5, CD39-FITC, HLA-DR-EF450, CCR6-FITC,
IL-1R1-CFS (all eBioscience), CD25-PE (BD), and CD45RA-AF700
(Biolegend) was carried out using an LSR II and FACSAria (both
BD), respectively. Appropriate isotype controls and Fluorescence
Minus One (FMO) controls were used to assign gates. ICS for
FOXP3 was carried out using the kit from eBioscience according
to manufacturer’s instructions. For co-staining of cytokines and
transcription factors, PMA (50 ng/mL), ionomycin (1 mM) (both
Sigma), and Brefeldin A (3 μg/mL; eBioscience) were added to
cell cultures 4.5 h before ICS with FOXP3, IL-17, and/or RORC
(all eBioscience) as required. All patient samples were collected
following informed written consent and studies were approved
by appropriate ethics committees.
Cell culture and suppression assays
Cells were cultured in complete medium as previously described
[56] and polyclonally activated with anti-CD3/CD28 microbeads
(Invitrogen) in the presence or absence of 10 ng/mL IL-1β (R&D
Systems), 10 IU/mL IL-2 (Roche), or 10 ng/mL IL-1β + 10 IU/mL
IL-2. Suppression of Teff-cell proliferation by Treg cells was
assessed using the standard CFSE dilution method [57] comparing
Teff cells cultured alone to those co-cultured 1:1 with Treg cells.
Cytokine measurement
Sandwich ELISA for human IL-17 (R&D systems) in T-cell super-
natants was carried out in duplicate according to manufacturer’s
instructions. Cytokine concentrations were interpolated from con-
temporaneously acquired standard curves.
Western blotting
Whole cell extracts were prepared by cell lysis in Laemmli
sample buffer. Proteins were resolved by SDS-PAGE on 8%
Tris-Glycine gels (Invitrogen) and electrotransferred onto
polyvinylidene fluoride membranes (Immobilon), Immunoblot-
ting was performed according to standard protocols, with
overnight incubation in primary antibodies: anti-pY-STAT3 Tyr
705, anti-PY-STAT5 (Cell Signaling, New England Biolabs), pan-
STAT5 (BD Biosciences), or anti-STAT3 (SantaCruz Biotechnol-
ogy) and 1-h incubation in appropriate secondary antibodies.
Bound antibodies were detected using ECL-Plus reagents (Pierce).
RNA extraction and qRT-PCR
RNA extraction (RNAqueous micro extraction kit (Ambion,
Applied Biosystems, CA, USA)) was followed by cDNA synthesis
using a VersoTM cDNA kit (Thermo Scientific). qRT-PCR was per-
formed in triplicate using the ABI Prism 7900 HT Sequence Detec-
tion System (SDS) and TaqMan gene expression kit (both Applied
Biosystems). Gene-specific primers (all from Applied Biosystems)
are shown in Supporting Information Table 1. Average CT values
were exported using SDS 2.3 software and normalized against the
control probe 18S using the formula 2ˆ[CT (18s)-CT (S)] where S =
sample.
Data analysis
Data analysis used Microsoft Excel and GraphPad Prism 5 (Graph-
Pad software, USA). Statistical analysis was performed by using
paired parametric and nonparametric tests as appropriate. Mul-
tiple datasets were compared by repeated measures ANOVA
(Tukey’s posthoc test) and Friedman tests (Dunns posthoc test)
for parametric and nonparametric data, respectively. A p value
< 0.05 was considered statistically significant.
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